3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
10
OTHER
2
NIH
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Gastrointestinal
1
Conditions
Carcinoma, Ovarian Epithelial
2
Interventions
Paclitaxel
268
Carboplatin
264
Cisplatin
194
Bevacizumab
135
pembrolizumab
99
Surveys and Questionnaires
84
Radiotherapy
77
Cyclophosphamide
75
olaparib
67
Blood Specimen Collection
65
Drug Therapy
62
Hyperthermic Intraperitoneal Chemotherapy
60
Gemcitabine
60
niraparib
56
Topotecan
56
Brachytherapy
54
liposomal doxorubicin
52
Taxes
47
Docetaxel
46
Magnetic Resonance Spectroscopy
43
Letrozole
36
Cytoreduction Surgical Procedures
36
Filgrastim
33
Biopsy
33
Surgical Procedures, Operative
32
durvalumab
31
Specimen Handling
31
Doxorubicin
31
Nivolumab
30
Albumin-Bound Paclitaxel
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
oregovomab
×
Gynecologic
×
Clear all
NCT03100006
2022-06-13
ORION-01
National Cancer Centre, Singapore
Phase 1/2
Terminated
13 enrolled
NCT04620954
2021-12-01
ORION-02
National Cancer Centre, Singapore
Phase 1/2
Unknown
31 enrolled